Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

9.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.6K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

7.2K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
7.2K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.4K
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

17
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
17
Detailed Structure and Function of Lymph Nodes01:23

Detailed Structure and Function of Lymph Nodes

13.3K
Lymph nodes are bean-shaped structures that cluster along the lymphatic vessels in the inguinal, axillary, and cervical regions. Each node is divided into compartments by a capsule that extends trabeculae inward.
From a histological perspective, lymph nodes can be split into two main areas: the superficial cortex and the deep medulla. The outer cortex is populated by dendritic cells, macrophages, and B lymphocytes, which are densely packed into follicles. When these B-lymphocytes are presented...
13.3K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.8K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial.

Blood advances·2026
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same author

Hybrid Supercharged Antibodies: A Rational Approach to Boost Immunoassay Sensitivity via Controlled Nanoparticle Adsorption.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.

Cancer science·2025
Same author

Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER).

Japanese journal of clinical oncology·2025
Same author

Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.

Japanese journal of clinical oncology·2025

Related Experiment Video

Updated: Apr 27, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

9.3K

[Hodgkin lymphoma].

Hirokazu Nagai

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 15, 2014
    PubMed
    Summary
    This summary is machine-generated.

    The standard ABVD therapy cures most Hodgkin lymphoma patients, but new molecular agents like brentuximab vedotin offer hope for refractory cases and may change future treatments.

    More Related Videos

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
    10:52

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

    Published on: March 30, 2018

    10.6K
    Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
    08:44

    Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

    Published on: September 7, 2022

    2.3K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
    08:53

    Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

    Published on: June 10, 2017

    9.3K
    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
    10:52

    Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

    Published on: March 30, 2018

    10.6K
    Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
    08:44

    Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

    Published on: September 7, 2022

    2.3K

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • The Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) regimen is the standard Hodgkin lymphoma treatment, achieving cure rates over 70% in many patients.
    • Despite the efficacy of ABVD, a subset of patients develop refractory disease, necessitating alternative therapeutic strategies.

    Purpose of the Study:

    • To review recent advancements in molecularly targeted agents for Hodgkin lymphoma.
    • To explore the potential of novel therapies, including antibody-drug conjugates and small molecules, in improving outcomes for relapsed and refractory Hodgkin lymphoma.

    Main Methods:

    • Literature review of clinical trials and research on novel molecularly targeted agents for Hodgkin lymphoma.
    • Analysis of data on the efficacy and safety of brentuximab vedotin, histone deacetylase inhibitors (HDACIs), and mTOR inhibitors in Hodgkin lymphoma.

    Main Results:

    • Brentuximab vedotin shows promise as a treatment for relapsed and refractory Hodgkin lymphoma and is being investigated for first-line therapy.
    • Small molecule inhibitors, including HDACIs and mTOR inhibitors, have demonstrated activity in patients with relapsed Hodgkin lymphoma.

    Conclusions:

    • Molecularly targeted agents represent a significant advancement in Hodgkin lymphoma treatment.
    • These novel therapies, including brentuximab vedotin and various small molecules, are poised to potentially alter the standard of care for Hodgkin lymphoma within the next decade.